The Drugs That Could Slow Aging Are Already Here | Dr. Nir Barzilai

Geroscience targets the underlying biology of aging to delay the onset of multiple age-related diseases simultaneously, shifting the medical focus from treating individual conditions to extending healthspan. Dr. Nir Barzilai, a pioneer in the field, emphasizes that aging drives pathologies like Alzheimer’s and cardiovascular disease, meaning interventions should occur before these conditions manifest. Existing FDA-approved drugs, such as SGLT2 inhibitors and metformin, demonstrate potential as geroprotectors by improving metabolic health and reducing all-cause mortality, though they require careful, supervised application. Future progress relies on developing robust biomarkers, such as proteomics, to quantify biological age and validate the efficacy of interventions. While the regulatory environment is increasingly receptive to longevity research, the field must prioritize rigorous clinical data over anecdotal supplement use to ensure safety and meaningful health outcomes.